• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc.

    11/14/24 6:42:29 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RARE alert in real time by email
    SC 13G/A 1 p24-3270sc13ga.htm ULTRAGENYX PHARMACEUTICAL INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 2)*
     

    Ultragenyx Pharmaceutical Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    90400D108

    (CUSIP Number)
     

    September 30, 2024

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G/A is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 90400D10813G/APage 2 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    RTW Investments, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    1,968,002 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    1,968,002 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,968,002 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.1%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

     

     

    CUSIP No. 90400D10813G/APage 3 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Roderick Wong, M.D.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    1,968,002 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    1,968,002 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,968,002 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.1%

    12

    TYPE OF REPORTING PERSON

    IN, HC

             

     

     

     

    CUSIP No. 90400D10813G/APage 4 of 7 Pages

     

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Ultragenyx Pharmaceutical Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 60 Leveroni Court, Novato, California 94949.

     

    Item 2(a). NAME OF PERSON FILING:

     

      This statement is filed by:
       
      (i)

    RTW Investments, LP ("RTW Investments"), a Delaware limited partnership, and the investment adviser to certain funds (the "RTW Funds"), with respect to the Shares (as defined in Item 2(d) below) directly held by the RTW Funds; and

     

      (ii) Roderick Wong, M.D. ("Dr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds.
         
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

      The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014.

     

    Item 2(c). CITIZENSHIP:
       
      RTW Investments is a Delaware limited partnership.  Dr. Wong is a citizen of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.001 per share (the "Shares").

     

     

     

    CUSIP No. 90400D10813G/APage 5 of 7 Pages

     

    Item 2(e). CUSIP NUMBER:
       
      90400D108

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) x

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:_________________________________________ _

     

    Item 4. OWNERSHIP:

     

       

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     

    The percentages set forth herein are calculated based upon 92,165,190 Shares outstanding as of July 29, 2024, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 2, 2024.

     

     

     

    CUSIP No. 90400D10813G/APage 6 of 7 Pages

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  ý

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
       
      See Item 2.  The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP:
       
      Not applicable.

     

    Item 10. CERTIFICATION:

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No. 90400D10813G/APage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: November 14, 2024

     

     

    RTW INVESTMENTS, LP
         
         
    By: /s/ Roderick Wong, M.D.  
    Name: Roderick Wong, M.D.  
    Title: Managing Partner  
         
         
         
    /s/ Roderick Wong, M.D.  
    RODERICK WONG, M.D.  
         

     

     

    Get the next $RARE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RARE

    DatePrice TargetRatingAnalyst
    3/24/2026$25.00Buy → Neutral
    Goldman
    10/20/2025$65.00Overweight
    Wells Fargo
    7/28/2025$80.00Buy
    H.C. Wainwright
    5/28/2025Outperform
    William Blair
    6/6/2024$56.00 → $67.00Neutral → Buy
    Goldman
    4/22/2024$77.00Outperform
    RBC Capital Mkts
    12/8/2023$72.00Overweight
    Wells Fargo
    6/14/2023$96.00Outperform
    Credit Suisse
    More analyst ratings

    $RARE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Horn Howard sold $110,602 worth of shares (4,653 units at $23.77), decreasing direct ownership by 4% to 105,689 units (SEC Form 4)

    4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

    6/1/26 7:11:52 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fust Matthew K was granted 7,751 shares, increasing direct ownership by 30% to 33,696 units (SEC Form 4)

    4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

    5/18/26 6:50:58 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suliman Shehnaaz was granted 7,751 shares and sold $144,189 worth of shares (5,740 units at $25.12), increasing direct ownership by 8% to 27,951 units (SEC Form 4)

    4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

    5/18/26 6:41:18 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RARE
    SEC Filings

    View All

    Ultragenyx Pharmaceutical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

    5/18/26 2:15:14 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Ultragenyx Pharmaceutical Inc.

    SCHEDULE 13G - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

    5/12/26 12:12:48 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ultragenyx Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

    5/5/26 4:06:15 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RARE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ultragenyx Pharma downgraded by Goldman with a new price target

    Goldman downgraded Ultragenyx Pharma from Buy to Neutral and set a new price target of $25.00

    3/24/26 8:28:47 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Ultragenyx Pharma with a new price target

    Wells Fargo initiated coverage of Ultragenyx Pharma with a rating of Overweight and set a new price target of $65.00

    10/20/25 8:02:57 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Ultragenyx Pharma with a new price target

    H.C. Wainwright resumed coverage of Ultragenyx Pharma with a rating of Buy and set a new price target of $80.00

    7/28/25 9:00:36 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RARE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

    NOVATO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's president and chief executive officer will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 4:00 PM ET. The live and archived webcast of the panel will be accessible from the company's website at https://ir.ultragenyx.com/events-presentations. About Ultragenyx Pharmaceutical Inc. Ultragenyx is a biopharmaceutical comp

    6/3/26 4:30:00 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    NOVATO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 17,567 restricted stock units of the company's common stock to 11 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of May 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4). T

    5/22/26 4:30:00 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference

    NOVATO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Howard Horn, the company's Chief Financial Officer and Executive Vice President and Joshua Higa, Chief of Staff and Vice President of investor relations, will participate in a fireside at Bank of America's 2026 Healthcare Conference on Tuesday, May 12, 2026, at 2:20 PM PT. The live and archived webcast of the panel will be accessible from the company's website at https://ir.ultragenyx.com/events-presentations. About Ultragenyx Pha

    5/6/26 4:30:00 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RARE
    Leadership Updates

    Live Leadership Updates

    View All

    Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

    NOVATO, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced the appointment of Eric Olson as chief business officer (CBO) and executive vice president effective September 22, 2025, following the planned retirement of Thomas Kassberg. Mr. Olson will be responsible for leading the company's business development, corporate development and alliance management functions. "We thank Tom for his 14 years of impactful contributions to Ultragenyx, including transformative business deals that helped build the largest clinical pipeline in rare disease; expanded our reach to patients with fatty acid oxidation diseases, X-linked hypophosphatemia, o

    9/30/25 4:05:00 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy

    NOVATO, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today announced that it has appointed Howard Horn as executive vice president and chief financial officer (CFO) effective October 16, 2023. Mr. Horn will be responsible for leading the finance, accounting, corporate strategy and investor relations functions. "Howard is joining Ultragenyx and its leadership team during a pivotal period as our robust late-stage pipeline is maturing and we are preparing for the next phase of company growth," said Emil D. Kakkis, M.D.,

    7/12/23 8:00:00 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President

    NOVATO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced that Eric Crombez, M.D., has been promoted to chief medical officer and executive vice president effective May 1, 2023, succeeding Camille Bedrosian, M.D., who will remain with the company in a full-time strategic advisory role. Dr. Crombez currently serves as Ultragenyx's chief medical officer for gene therapy and inborn errors of metabolism. "Eric has extensive expertise in the development and execution of clinical development programs for rare genetic disorders and has been a driving force for our entire gene therapy pipeline," said Emil D. Kakkis, M.D., Ph.D., chief executive of

    3/14/23 8:30:00 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RARE
    Financials

    Live finance-specific insights

    View All

    Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update

    First quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 million and combined R&D and SG&A expenses to be flat to slightly down versus 2025; remain on path to profitability in 2027 GTX-102 for Angelman syndrome: New longer-term data from Phase 1/2 clinical study support durable and improving effects across multiple domains; Phase 3 data expected in the second half of 2026 NOVATO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel

    5/5/26 4:01:00 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update

    NOVATO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, May 5, 2026, to discuss its financial results and corporate update for the quarter ending March 31, 2026. The live and replayed webcast of the call will be available through the company's website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months. About Ultragenyx Pharmaceutical Inc.Ultragenyx is a biopharmaceutica

    4/29/26 8:00:00 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

    2025 total revenue of $673 million,Crysvita® revenue of $481 million and Dojolvi® revenue of $96 million 2026 total revenue from current products expected to be between $730 million to $760 million Initiated a strategic restructuring plan to significantly reduce and focus expenses and headcount, reiterate path to profitability in 2027 2026 catalysts include two potential approvals and expected pivotal Phase 3 data from the GTX-102 Phase 3 Aspire study for Angelman syndrome NOVATO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and

    2/12/26 4:01:00 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RARE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc.

    SC 13G/A - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

    11/14/24 6:42:29 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc. (Amendment)

    SC 13G/A - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

    2/14/24 10:03:02 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc. (Amendment)

    SC 13G/A - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

    2/14/24 7:46:34 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care